Hematopoietic stem cell transplantation-associated partial lipodystrophy.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Oncology Survivorship

Background:

• Hematopoietic stem cell transplantation-associated partial lipodystrophy (HSCT-PL) is a recognized metabolic complication in childhood cancer survivors post-total body irradiation (TBI).
• HSCT-PL presents with significant metabolic dysfunction, including insulin resistance, diabetes, hypertriglyceridemia, and hepatic steatosis.
• The condition is characterized by a specific phenotype involving fat distribution changes (lipoatrophy and lipohypertrophy).

Purpose of the Study:

• To review and synthesize current knowledge on HSCT-PL, including its clinical presentation, potential pathogenesis, and epidemiological characteristics.
• To identify knowledge gaps concerning diagnosis, prognosis, and treatment strategies for HSCT-PL.
• To explore potential therapeutic avenues, such as metreleptin.

Main Methods:

• Literature review of 12 reports detailing 17 patients with HSCT-PL.
• Analysis of clinical data, metabolic profiles, and epidemiological features.

Main Results:

• A review identified 17 HSCT-PL patients, noting a strong female predominance (15/17) and a potential ethnic predisposition (11/17 Japanese).
• Radiation-induced damage to adipose progenitor cells, leading to senescence, is hypothesized as a primary pathogenic mechanism.
• Observed metabolic dysfunction includes insulin resistance, diabetes, elevated triglycerides, hepatic steatosis, visceral fat accumulation, and increased waist-to-hip ratio.

Conclusions:

• HSCT-PL is an increasingly recognized distinct disease entity with profound metabolic consequences.
• Further research is crucial for establishing diagnostic criteria, understanding long-term outcomes, and developing effective treatments.
• Metreleptin shows promise as a therapeutic option, warranting further investigation into its efficacy.